Human papillomaviruses (HPV) are small double-stranded DNA viruses with over 180 genotypes that infect mucosal and cutaneous basal epithelia. It has been estimated that up to 80% of sexually active individuals will become infected in their lifetime, making HPV the most common sexually transmitted pathogen 1 . HPVs are classified as high-and low-risk genotypes based on their oncogenic potential 2 . High-risk HPVs are causally associated with ~5% of human cancers including nearly all cervical cancer (CxCa) and about 25% of head and neck cancer (HNC), making HPV a significant cause of morbidity and mortality worldwide 2, 3 . While the majority of primary HPV infections are cleared within two years, ~10% of infected individuals establish a lifelong persistent infection 4 . Similar studies have revealed that, of the genotypes tested, HPV16 is the most likely to persist 5 . Given the propensity of HPV to persist without eliciting a strong immune response, it is very likely that the virus has evolved efficient immune evasion mechanisms.
Human papillomaviruses (HPV) are small double-stranded DNA viruses with over 180 genotypes that infect mucosal and cutaneous basal epithelia. It has been estimated that up to 80% of sexually active individuals will become infected in their lifetime, making HPV the most common sexually transmitted pathogen 1 . HPVs are classified as high-and low-risk genotypes based on their oncogenic potential 2 . High-risk HPVs are causally associated with ~5% of human cancers including nearly all cervical cancer (CxCa) and about 25% of head and neck cancer (HNC), making HPV a significant cause of morbidity and mortality worldwide 2, 3 . While the majority of primary HPV infections are cleared within two years, ~10% of infected individuals establish a lifelong persistent infection 4 . Similar studies have revealed that, of the genotypes tested, HPV16 is the most likely to persist 5 . Given the propensity of HPV to persist without eliciting a strong immune response, it is very likely that the virus has evolved efficient immune evasion mechanisms.
Dysregulation of host gene expression is a well-known strategy that viruses frequently employ to evade the host immune response. Of note, Epstein-Barr virus (EBV) hijacks host cell epigenetic machinery to modulate host gene expression 6 . These epigenetic manipulations are considered a hallmark of EBV-induced lymphomas, and persist even after infection is cleared 6, 7 . Interestingly, HPV-positive HNC and CxCa progression exhibit distinct changes in host DNA methylation that alter host gene expression 8, 9 . In a similar study, HPV-induced cell immortalization corresponded with hypermethylation at several host chromosomal loci including the telomerase subunit hTERT 10 . Expression of hTERT is increased by promoter hypermethylation which correlates with HPV-associated transformation and cancer progression Interestingly, E7 directly binds and activates DNA methyltransferase 1 (DNMT1), leading to a potential epigenetic mechanism of E7-mediated transcriptional modulation 12, 13 . Consistently, the HPV E7-DNMT1 complex induces hypermethylation of the tumor suppressor cyclin A1 (CCNA1) promoter, an epigenetic marker strongly correlated with HPV-associated malignancy 13, 14 . Further, our recent work has revealed that the chemokine CXCL14 is significantly downregulated by E7-directed promoter hypermethylation 15 . Restoration of CXCL14 expression in HPV-positive cancer cells prevents tumor formation in vivo and increases natural killer (NK) and CD8
+ T cell populations in the tumor-draining lymph nodes 15 . Downregulation of CXCL14 is therefore an important immune evasion mechanism employed by HPV E7, allowing for virus persistence. Thus, it is likely that HPV E7 dysregulates expression of other host genes by modulating DNA methylation to establish persistent virus infection.
To identify key host factors and pathways altered by HPV-directed DNA methylation in human keratinocytes, we performed parallel global gene expression and DNA methylation analyses. Here, we report that most class I major histocompatibility complex (MHC-I) molecules are transcriptionally downregulated in an E7-dependent manner. Further, non-classical HLA-E, which regulates NK and CD8
+ T cells, is significantly downregulated by E7-mediated hypermethylation in a distal regulatory CpG island (CGI). These results suggest that HPV E7-mediated DNA methylation may modulate host immune responses by downregulating HLA-E expression.
Results
The HPV oncoprotein E7 drives global gene expression changes in human keratinocytes. To determine gene expression alterations in human keratinocytes by high-risk HPVs, we performed global gene expression analysis in normal immortalized keratinocytes (NIKS) and their derivatives: NIKS-16 and NIKS-18 cells containing episomal HPV16 and HPV18 genomes, respectively. NIKS-16ΔE7 cells containing the HPV16 genome lacking E7 expression 16 were used to investigate the roles of the HPV oncoprotein E7. Global gene expression profiles of these cells were analyzed using Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays (GEO accession # GSE83259). Principal component analysis (PCA) of normalized mRNA expression profiles demonstrated that NIKS-16 and NIKS-18 cells clustered together distinctly from NIKS and NIKS-16ΔE7 cells (Fig. 1a) . NIKS-16ΔE7 cells, growing slower than the parental NIKS cells, are more morphologically diverse compared to the other NIKS cells tested. These differences may be reflected to high variations between replicates shown by PCA (Fig. 1a) .
High-risk HPV infection significantly changes host gene expression patterns including dramatic upregulation of DNA replication-and cell cycle-related gene expression 17, 18 . However, the extent of E7-specific gene expression changes has not been fully determined. To define E7-mediated gene expression changes in keratinocytes, we analyzed global gene expression and defined genes up-or downregulated in both comparisons of NIKS-16 vs. NIKS cells and NIKS-16 vs. NIKS-16ΔE7 cells. We identified 625 upregulated and 849 downregulated genes exhibiting a false discovery rate (FDR)-adjusted p-value of less than 0.05 for each comparison and a change greater than 30% magnitude in expression (Fig. 1b, Table S1 ). To examine the physiological relevance of HPV-specific gene expression changes, we analyzed the expression patterns of distinct cell cycle-specific genes which were previously identified using CxCa, HNC, and normal patient tissue samples 17 . Consistent with the results from patient tissues, the majority of the cell cycle genes upregulated in HPV-positive cancers were markedly increased in NIKS-16 and NIKS-18 cells compared to NIKS cells, while none of the cell cycle genes upregulated in HPV-negative HNC tissues were increased in NIKS-16 and NIKS-18 cells (Fig. 1c) . Interestingly, most of the upregulated genes in NIKS-16 and NIKS-18 cells were not changed or were slightly downregulated in NIKS-16ΔE7 cells compared to NIKS cells. These results indicate that the distinct patterns of cell cycle dysregulation in HPV-positive cancers are largely caused by the HPV oncoprotein E7. Using RT-qPCR, we further validated expression changes of selected genes from Fig. 1c (CDKN2A and MCM7) and previously reported (UHRF1 and MCM5) 17, 18 (Fig. 1d) . These results indicate a significant role of the HPV oncoprotein E7 in global gene expression changes during persistent HPV infection in keratinocytes including cell cycle-related genes.
The HPV oncoprotein E7 downregulates gene expression related to antigen presentation. To understand the biological functions of the identified HPV16 E7-regulated genes (Table S1 ), we performed pathway analysis using Reactome (reactome.org). Consistent with our previous findings 17, 18 , the majority of the upregulated genes were involved in cell cycle progression, DNA replication, and DNA repair (Table S2 , Fig. S1a ). In contrast, the pathways of downregulated genes are diverse, suggesting that E7-mediated downregulation of gene expression is more complex than E7-mediated upregulation of gene expression. Interestingly, our analysis revealed that genes involved in antigen presentation, IL1 signaling, and extracellular matrix degradation are significantly downregulated in NIKS-16 cells compared to NIKS and NIKS-16∆E7 cells (Table S2 , Fig. S1b ). Various matrix metalloproteinases and kallikreins were significantly downregulated in NIKS-16 cells compared to NIKS and NIKS-16ΔE7 cells (Table S2 , Fig. S2a) .
Importantly, immune response pathways were among the most significantly affected by HPV16 E7 expression (Fig. S1b,Table S2 ). Several genes in antigen presentation (e.g. HLA-B, HLA-E, SEC31A, ITGAV, CTSL2, and RNASEL) and IL1 signaling (e.g. IL1B, IL1R1, IL1RN, and IL36G) were significantly altered in NIKS-16 and NIKS-18 cells, but not in NIKS-16ΔE7 cells, compared to NIKS cells ( Fig. S2b and S2c) . Using RT-qPCR, we further validated E7-dependent dysregulation of genes involved in IL1 signaling (Fig. S2d) . Previous studies have shown that HPV16 E5 disrupts trafficking of MHC-I and -II complexes to the cell surface, and HPV16 E7 downregulates cell surface expression of MHC-I complexes [19] [20] [21] . While multiple mechanisms of inhibiting MHC-I surface expression have been observed, HPV-mediated alterations in MHC-I gene expression is poorly understood. Thus, we further assessed expression of all MHC-I α-subunits (HLA-A, -B, -C, -E, -F, and -G) in the NIKS cell lines. The results showed that expression of all MHC-I α-subunit genes, except for HLA-F, was downregulated in NIKS-16 and NIKS-18 cells compared to NIKS and NIKS-16∆E7 cells (Fig. 2a) . To determine any difference in MHC-I gene expression between HPV-positive and HPV-negative cancer tissues, we analyzed the TCGA data of HNC and CxCa obtained from cBioPortal. Interestingly, the expression levels of HLA-C and HLA-E were significantly lower in HPV-positive HNCs and CxCa than HPV-negative HNCs (Fig. 2b) . This observation underscores the effect of HPV on HLA gene expression in HPV-associated disease. Unfortunately, due to the presence of numerous splice isoforms for MHC-I genes, we were unable to reliably detect amplicons from MHC-I mRNA transcripts by RT-qPCR. However, all array probesets for HLA-A, -B, -C, -E and -G detection consistently exhibit significant downregulation in HPV-positive keratinocytes in an E7-dependent fashion (Fig. 2a) . Overall , and UHRF1 expression levels were determined by RT-qPCR and normalized to β-actin expression levels. Each sample was quadruplicated, and shown are representative of three repeats. Fold changes compared to NIKS cells are plotted. P-values were calculated by Student's t test. *p < 0.0001, **p < 0.001, ***p < 0.01, ****p < 0.05. downregulation of MHC-I genes suggests that HPV16 E7 plays an important role in immune dysregulation of HPV-infected keratinocytes by altering immune cell recognition during early stages of persistent infection.
The HPV oncoprotein E7 dysregulates DNA methylation in human keratinocytes. A previous study has shown that HPV infection distinctly modifies the DNA methylation patterns in HNC patients 22 . Additionally, HPV16 E7 protein directly binds to DNMT1 and activates its enzymatic activity 12 . We recently reported that E7-dependent methylation of the CXCL14 promoter resulted in CXCL14 downregulation and inhibition of antitumor immune responses 15 . These findings suggest that high-risk HPV E7 is very likely to dysregulate host gene expression by modulating DNA methylation. To investigate the extent of gene expression dysregulated by HPV E7-induced DNA methylation, we analyzed the methylome of NIKS, NIKS-16, NIKS-18, and NIKS-16ΔE7 cell lines in triplicate using Illumina Infinium HumanMethylation450 BeadChip arrays (GEO accession # GSE83261). PCA of methylome showed that each cell type clustered distinctly (Fig. 3a) . Given that the PCA from our gene expression analysis showed high similarity between NIKS-16 and NIKS-18 cells (Fig. 1a) , the methylome data may discriminate the molecular patterns of different cell types more precisely than the gene expression data. The sample-by-sample variations in the triplicates of each cell line are much lower in the methylome data ( Fig. 3a ) than in gene expression data (Fig. 1a) . This implies that DNA methylation could be a better biomarker than gene expression for early detection of high-risk HPV infection. By assessing the relative methylation density at any given CpG site across the genome, we found that NIKS cells tended to maintain β-values (the ratio of methylated probe intensity vs. the overall intensity) near 0 (0% methylation) or 1 (100% methylation) with uniform distribution between those two peaks on both flanks (Fig. 3b , black line). In contrast, both NIKS-16 and NIKS-18 cells exhibited an influx in hemi-methylation near β = 0.6 ( Fig. 3b , red and orange lines). Interestingly, the methylation pattern of NIKS-16ΔE7 cells was strikingly similar to the methylation pattern of NIKS cells but distinct from the methylation pattern of NIKS-16 and NIKS-18 cells (Fig. 3b , blue line). These results suggest that E7 alters the global methylation patterns of the host genome.
To validate our methylome array data, we assessed DNA methylation status at the CCNA1 and TERT promoter regions that are known to be hypermethylated in HPV-positive cells. Consistent with previous findings, the CCNA1 and TERT promoter regions showed significantly increased methylation (24-28% increase in β, p < 0.004) in NIKS-16 cells compared to NIKS cells (Table S3) 10, 13, 14, 23 . However, NIKS-18 cells did not show consistent changes in CCNA1 and TERT promoter methylation. Given that the global methylome data showed the distinct DNA methylation patterns between NIKS-16 and NIKS-18 cells, these results suggest that HPV16 and HPV18 may differentially modulate host DNA methylation. A genome-wide comparison of methylated CpG sites unique between NIKS and NIKS-16 cells revealed 5,190 differentially methylated positions (DMPs, defined as a single differentially methylated CpG site) and 1,307 differentially methylated regions (DMRs, defined as a cluster of two or more CpG sites, permutation p-value < 0.05) ( Fig. 3c and d) . To investigate DNA methylation specifically regulated by HPV16 E7, we identified 953 DMRs (red bold in Fig. 3d ) in the overlap of the comparison between NIKS-16 and NIKS cells with the comparison between NIKS-16 and NIKS-16ΔE7 cells, excluding the DMRs found in the comparison between NIKS-16ΔE7 to NIKS cells. Using a more stringent DMR area p-value less than 0.01, we identified 56 hypermethylated DMRs (Table S4) and 47 hypomethylated DMRs (Table S4 ) that are dependent on HPV16 E7 expression. Interestingly, regional methylation analysis near HLA-E identified two significantly hypermethylated DMRs across a total of 5 probed CpG sites (p ≤ 0.004, Table S4 ), suggesting that HPV16 E7 may mediate DNA methylation of the HLA-E gene.
To determine gene expression regulated by E7-mediated DNA methylation, we identified genes that show gene expression changes (>30%) with an FDR adjusted p-value less than 0.01 and associated DMPs with an FDR adjusted p-value less than or equal to 0.005 between NIKS and NIKS-16 cells (Table S5) . DMPs rather than DMRs were used in this analysis to reduce the possibility of type II errors: the locations of methylation array probes are predicted to be sentinel CpG sites and may not be clustered near additional probes, thus potential true positives may be eliminated from DMR classification. A total of 83 genes showed significant changes of both gene expression and DNA methylation comparing NIKS-16 cells to NIKS cells. This result is consistent with a previous global DNA methylation study assessing epigenetic changes directed by EBV, showing that most DMPs are silent and relatively a small number of them contributed to gene expression changes 7 . Our results suggest that E7-mediated DNA methylation regulates gene expression of a subset of host genes. Interestingly, HLA-E shows a significant decrease in gene expression and increase in DNA methylation (Figs 2 and 4) . Consistent with the HLA-E gene expression results, the comparison between NIKS-16 and NIKS-16ΔE7 cells showed a significant decrease in DNA methylation at HLA-E (24%) in NIKS-16ΔE7 cells compared to NIKS-16 cells (Table S5 ). These results suggest that downregulation of HLA-E gene expression shown in Fig. 2a is likely caused by HPV16 E7-mediated DNA methylation.
DNA methylation of the HLA-E CGI is significantly increased by the HPV oncoprotein E7. Our methylome data consistently showed that DNA methylation of HLA-E was significantly increased in NIKS-16 cells compared to NIKS cells in an E7-dependent manner (Table S5) . Unexpectedly, the HLA-E CGI containing the identified DMR is ~23,000 bases upstream of the HLA-E open reading frame (ORF), potentiating its functional role as an enhancer or distal promoter element. Our results from scanning the HLA-E CGI for DNA methylation showed a dramatic increase (~50%) near the 3′ region of the CGI (Fig. 4a) . To validate DNA methylation in the HLA-E CGI, we performed methylation-specific PCR (MSP) using primer sets specific to the HLA-E DMR. Consistent with the methylome data, the 3′ region of the HLA-E CGI was highly methylated in NIKS-16 cells compared to NIKS cells, but the HLA-E CGI methylation dramatically decreased in NIKS-16ΔE7 cells (Fig. 4b) . The DNA methylation of the HLA-E CGI is highly correlated with the decrease of HLA-E expression in NIKS-16 cells, but not in NIKS-16ΔE7 cells (Fig. 2a) . These results suggest that HLA-E gene expression may be downregulated by HPV16 E7-mediated DNA methylation.
HPV16 E7 directly binds and activates DNMT1 through its CR3 zinc finger binding domain, providing a potential mechanism of E7-induced DNA methylation 12 . However, it is unclear how E7-mediated DNA methylation targets specific regions in the genome. We hypothesized that the regions near specific transcription factor (TF) binding sites are targeted by the E7-DNMT1 complex to direct DNA methylation. Supporting our hypothesis, a previous study revealed that HPV16 E7 recruits histone deacetylases (HDACs) to IRF-1 regulatory promoter complexes thereby directing histone deacetylation to silence IRF-1 responsive genes 24 . To test our hypothesis, we compiled a list of hypermethylated DMRs, filtered as described above, for E7-dependent hypermethylation (p < 0.04, count 185) and submitted DMRs with 100 bp of flanking sequence to MEME suite for enrichment analysis of TF binding motifs. Interestingly, E7-dependent hypermethylated DMRs showed enrichment of EPAS1, FOXJ3, CDX2, IRF4, FOXF1, and glucocorticoid receptor (GCR) TF binding sites (Fig. 4c) . Enrichment of IRF4, FOXF1, and GCR motifs imply that E7-mediated DNA methylation may be directed to TF binding motifs near immunoregulatory and developmental genes [25] [26] [27] [28] . Consistently, scanning the HLA-E CGI (containing the identified DMR) for TF binding sites identified a GCR consensus binding motif, AGAACA (Fig. 4c) . Previous studies have shown that GCR is involved in suppression of MHC-I 27 and MHC-II expression 29 . Enrichment of methylation near specific TF binding sites implies that HPV E7 may direct DNA methylation by recruiting DNMT1 methyltransferase to specific promoter elements through interactions with TFs (Fig. 4d) . Further analysis revealed that the HLA-E CGI contains sites for DNase I hypersensitivity and acetylated H3K27 histone markers, both indicative of active regulatory elements. Additionally, small noncoding RNAs (ncRNAs) are transcribed from 3′ of the HLA-E CGI (Fig. S3) . MicroRNA target prediction analysis of these ncRNAs revealed 65 putative target cellular mRNAs (Table S6) , including histocompatibility 13 (HM13), which is involved in loading peptides onto HLA-E. HLA-E surface expression and stabilization require antigen binding, suggesting a potential mechanism of downregulating HLA-E surface expression 30 . Taken together, the HLA-E CGI appears to be an active site for transcription of ncRNAs and other regulatory elements which may have direct or indirect effects on HLA-E expression.
The promoter activity of the HLA-E CGI is repressed by DNA methylation. To assess the transcriptional regulation by DNA methylation at the HLA-E CGI, we employed a promoter reporter assay using a CpG-free firefly luciferase expression vector, pCpGL-Basic 31 . We first determined the promoter and/or enhancer activity of the HLA-E CGI by cloning the HLA-E CGI (hg19, chr6:30,434,030-30,434,730) into the pCpGL-Basic vector. pCpGL-HLAE-CGI constructs were prepared to test the promoter activity of the HLA-E CGI in forward and reverse orientations (pCpGL-HLAE-Fwd and pCpGL-HLAE-Rev). Additionally, we tested the enhancer activity of the HLA-E CGI in combination with a downstream EF1α promoter (pCpGL-HLAE-Fwd-EF1α and pCpGL-HLAE-Rev-EF1α) (Fig. 5a ). Each construct was transfected into 293FT cells along with a Renilla luciferase vector as a transfection control. Promoter activity was determined by relative luciferase activity. Our results revealed the strong promoter activity of the HLA-E CGI, showing near 200-fold and 130-fold increases in luciferase activity by insertion of the HLA-E CGI in forward or reverse orientations, respectively (Fig. 5b) .
We next tested if hypermethylation in the HLA-E CGI represses its promoter activity using in vitro DNA methylation. The pCpGL reporter constructs were methylated in vitro using the M.SssI CpG methyltransferase. To verify successful DNA methylation of the pCpGL reporter constructs, methylated and unmethylated plasmids were digested with restriction enzymes BstUI and McrBC, which cut only unmethylated and methylated CpG motifs, respectively (Fig. 5c) . Each methylated and unmethylated plasmid was transfected into 293FT cells and relative luciferase activity was measured. The CpG-free pCpGL-CMV-EF1α plasmid (unaffected by CpG methylation) was used as a negative control 31 and the pCpGL-CXCL14 promoter (repressed by CpG methylation) plasmid and pCpGL-CRE4X (activated by CpG methylation) plasmid were used as positive controls 15, 32 . Interestingly, in vitro DNA methylation dramatically decreased the luciferase activity of all HLA-E CGI containing reporter plasmids (Fig. 5d) . As expected, while the luciferase activity of pCpGL-CMV-EF1α was unchanged, the luciferase activity of pCpGL-CXCL14 and pCpGL-CRE4X were significantly decreased and increased by in vitro DNA methylation, respectively (Fig. 5d) . These results suggest that HLA-E expression is negatively regulated by DNA methylation in the HLA-E CGI. Methylation specific PCR (MSP) products were separated in 2% agarose gel to evaluate the methylation status of the HLA-E CGI using bisulfite-converted gDNA from NIKS, NIKS-16, and NIKS-16ΔE7 cells and primers listed in Table S7 . (c) Sequence logos of enriched transcription factor (TF) binding motifs are shown. 100 bp regions flanking E7 sensitive DMRs (comparing NIKS to NIKS-16 cells, p < 0.04, count 185) were assessed for enrichment of TF binding motifs using MEME Suite software and nucleotide frequencies in the submitted sequences as background (enrichment p < 0.05). (d) Schematic diagram of the potential mechanism of targeted E7-induced DNA methylation. E7 binds transcription factors (or complexes) through its CR1/2 domain and DNMT1 through its CR3 domain, leading to hypermethylation near specific transcription factor binding motifs.
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HLA-E protein expression is downregulated by high-risk HPV E7, but not by low-risk HPV E7. To determine if HLA-E protein levels are also decreased by E7, cell surface expression of HLA-E proteins was determined in NIKS, NIKS-16, and NIKS-18 cells by flow cytometry. Gating for flow cytometry and staining controls are shown in Figs S4 and S5, respectively. As previous studies have shown that surface expression of MHC-I molecules is frequently downregulated in HPV-positive cells and tissues 33 , we also examined HLA-B/C expression in NIKS, NIKS-16, and NIKS-18 cells. Consistent with our mRNA expression data, protein expression of HLA-E as well as HLA-B/C was dramatically decreased in NIKS-16 and NIKS-18 cells compared to NIKS cells ( Fig. 6a and b) . As shown above, HPV16 E7 expression is necessary for HLA-E downregulation (Fig. 2a) . To test if expression of high-risk E7 is sufficient for HLA-E downregulation, we generated stable NIKS cell lines expressing E7 from high-risk HPV genotypes (16 and 18) and low-risk HPV genotypes (6 and 11). E7 expression in each NIKS cell line was validated by RT-PCR (Fig. S6) , as antibodies detecting E7 from different genotypes are not available. Interestingly, high-risk HPV16 E7 or HPV18 E7 expression was sufficient to decrease HLA-E proteins on NIKS cells, while low-risk HPV6 E7 or HPV11 E7 expression rather increased HLA-E expression on NIKS cells (Fig. 6c and d) . In contrast, low-risk E7 expression moderately decreased HLA-B/C expression compared to substantial downregulation of HLA-B/C by high-risk E7 expression (Fig. 6e and f) . These results highlight the distinct functions of high-risk and low-risk E7 proteins in dysregulation of MHC-I expression.
As we showed that demethylation at the HLA-E CGI restored HLA-E gene expression, we treated NIKS-16 cells with the demethylating agent, 5-aza-2′-deoxycytidine (5-aza). Interestingly, 5-aza treatment dramatically restored HLA-E protein expression on NIKS-16 and NIKS-18 cells (Fig. 6g and h ). Demethylation at the HLA-E CGI with 5-aza treatment in NIKS-16 cells was verified by MSP (Fig. S7) . Taken together, our findings suggest . High-risk HPV E7, but not low-risk HPV E7, is sufficient for downregulation of HLA-E protein expression in keratinocytes. NIKS and NIKS derivative cells were dissociated to single cell populations using citric saline buffer, fixed in 4% paraformaldehyde, incubated with anti-HLA-E or anti-HLA-B/C antibodies, and assessed by flow cytometry as described in Supplementary Methods. HLA-E (a) and HLA-B/C (b) protein expression in NIKS (grey) and NIKS-16 (red) cells. (c-f, and h) NIKS cells stably expressing E7 from HPV6, 11, 16, and 18 (NIKS-6E7, NIKS-11E7, NIKS-16E7, and NIKS-18E7, respectively) were generated by lentiviral transduction followed by puromycin selection. HLA-E (c and d) and HLA-B/C (e and f) expression in NIKS cells (grey) and NIKS cells expressing high-risk (HPV16 and 18, red) or low-risk (HPV6 and 11, blue) E7 was analyzed by flow cytometry. HLA-E expression in NIKS-16 cells mock treated (grey) or treated with 5 μM 5-aza (red) for five days was assessed by flow cytometry (g and h) . Shown are representative data of three repeats.
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Discussion
Our previous global gene expression studies using CxCa and HNC patient tissue samples have shown that expression of cell cycle-related genes is highly upregulated in HPV-positive cancers compared to normal tissue and HPV-negative HNC 17, 18 . Additionally, other studies have shown that HPV alters global DNA methylation as a mechanism to silence host gene expression using genetically dissimilar HNC tissues and cell lines 22, 34 . In parallel gene expression and methylome analyses using homogeneous keratinocytes, we found that the HLA-E CGI is hypermethylated in HPV-positive cells in an E7-dependent manner, correlating with downregulation of HLA-E expression. Previous studies have shown that DNA hypermethylation is an effective mechanism of repressing MHC-I and -II gene expression, which is reversed by methylation inhibitors 35, 36 ; however, any effect of HPV on HLA-E expression was unknown.
MHC expression is modulated by various cellular mechanisms. For example, the HLA-G promoter contains a series of cis regulatory elements that govern tissue-specific expression 37 . Distal promoter elements are scattered throughout the MHC gene locus and activate transcription of ncRNAs that may regulate expression of the MHC genes 38 . One distal regulatory element has been characterized 25 kb upstream of the HLA-DRA promoter 39 . Similarly, we here report that a distal CGI located 23 kb upstream of the HLA-E ORF exhibits strong promoter activity. We showed that the HLA-E CGI remains hypomethylated in normal (NIKS) cells (β = 12.4%), but hypermethylated in NIKS-16 cells (change in β > 50%) and its methylation is linked to HLA-E downregulation. Thus, it is possible that HPV E7-induced DNA methylation silences promoter activity of the distal HLA-E CGI, or silences expression of a regulatory ncRNA which may modulate HLA-E regulatory elements, as previously hypothesized 38 . Additionally, DNase I hypersensitivity (indicative of a relaxed chromatin structure), H3K27 acetylation (a histone marker synonymous with active transcription) 40 , conserved TF binding sites, and ncRNAs from this region indicate that the HLA-E CGI is an active regulatory region for HLA-E expression (Fig. 4c, Fig. S3 ).
It has been suggested that HPV E7 inhibition of STAT1 activation represses TAP1 transcription, which leads to a decrease of surface expression of MHC-I molecules 41 . However, the TAP1 mRNA levels were not changed in either NIKS-16 or NIKS-18 cells compared to NIKS and NIKS-16∆E7 cells (data not shown). This observation suggests that downregulation of HLA-B/C protein expression in NIKS-16 and NIKS-18 cells might not be mediated by E7-induced TAP1 downregulation. Here, our study showed that HLA-E expression is regulated by DNA methylation and is restored by treatment of a demethylating agent. In contrast, the HLA-B/C gene regions showed no significant changes in DNA methylation induced by HPV16 or HPV18. Thus, HLA-B and -C downregulation is likely caused by HPV E7, but is mediated by other unknown mechanisms. Interestingly, the MHC-I transactivator NLRC5, which is necessary for MHC-I gene expression and repressed by DNA methylation in various cancers 42 , was downregulated in NIKS-16 and NIKS-18 cells when compared to NIKS and NIKS-16ΔE7 cells (Table S1 ). This may in part explain E7-dependent downregulation of HLA-B/C expression, while further studies are essential to fully understand the mechanism.
HLA-E is constitutively expressed in various tissues and at different stages in development, suggesting tight spatial-temporal regulation of expression 43 . We observed that HLA-E expression in NIKS cells is not homogeneous (Fig. 6 ). This may be due to heterogeneous populations and/or the nature of the co-culture model with feeders wherein NIKS cells propagate in islands with visually distinct morphologies depending on their relative position to other NIKS cells. It would be interesting, therefore, to further explore HLA-E expression in distinct layers of three-dimensional tissue, which may also dictate HLA-E functionality.
HLA-E regulates NK and T cells through direct contact with surface receptors. The NK cell inhibitory receptor NKG2A and the activating receptor NKG2C were initially found to bind HLA-E on the cell surface 44 . HLA-E presentation of MHC leader peptides to NK cells leads to NKG2A-mediated inhibition of NK effector function 44, 45 . Interestingly, HLA-E presentation of stress-inducible heat shock protein 60 peptides interferes with NKG2A recognition, leading to NK cell-mediated killing of stressed cells 46 . In addition to regulating NK cells, HLA-E also acts on CD8 + T and natural killer T (NKT) cells to modulate adaptive immune responses 47, 48 . HLA-E activates or inhibits NK and CD8 + T cell functions by presenting a narrow range of viral and bacterial antigens 49 . Of note, a viral-derived peptide presented by HLA-E on HIV-1-infected CD4 + T cells activates NK cells and induces cytolysis of virus-infected cells 50 . In contrast, a viral peptide presented by HLA-E on the surface of hepatitis C virus-infected cells inactivates NK cells but elicits HLA-E-restricted CD8 + T cell responses 51 . These findings imply that HLA-E has the potential to present HPV-derived peptides to NK or CD8 + T cells, which may lead to lysis of the HPV-infected cells. Interestingly, we have previously found that high-risk HPV E7 significantly reduces NK and CD8 + T cell infiltration into the HPV-positive tumor microenvironment through CXCL14 downregulation by its promoter hypermethylation 15 . Together, these results suggest that HPV evades antiviral NK and CD8 + T cell activity by dysregulating DNA methylation. In contrast, HLA-E is upregulated in several cancers, including HNC, CxCa, breast, rectal, colon, and ovarian cancers 8 . Accordingly, it has been speculated that the high levels of HLA-E may inhibit NK cell activation caused by downregulation of classical MHC-I expression on cancer cells. The better survival rate of ovarian cancer patients with infiltrating CD8 + T cells disappears when NKG2A signaling is activated by high HLA-E expression 52 . HLA-E expression is also linked to poor clinical outcome and low overall survival in breast and colon cancer patients 53, 54 . Further, knockdown of HLA-E expression enables NKG2D-mediated lysis of glioma cells by NK cells 55 . Our results showing that high-risk HPV E7 downregulates HLA-E expression imply dual roles of HLA-E that induces antiviral immunity in normal cells but suppresses antitumor immunity in cancer cells.
Indeed, previous studies have shown that HLA-E plays an important role in antiviral immune responses. HLA-E presentation of viral peptides elicits cytotoxic responses of NK and CD8
+ T cells that kill virus-infected cells 50, 51, 56 . We report here that high-risk HPV E7 significantly downregulates HLA-E expression in keratinocytes, while low-risk HPV E7 increases HLA-E expression. The epigenetic repression of HLA-E expression by E7 suggests a previously undescribed immune evasion mechanism employed by high-risk E7, but not by low-risk E7. Additionally, HLA-E expression can be restored through treatment with the demethylating agent, 5-aza. This may provide a new therapeutic approach to treat HPV-positive lesions by activating the HLA-E mediated antitumor immune responses of NK and CD8 + T cells.
Methods
Cell Culture. Human keratinocytes NIKS 57 , NIKS-16, NIKS-18 58 , and NIKS-16ΔE7 16 cells were co-cultured with NIH 3T3 feeder cells in E-complete medium as previously described 17 . NIKS-6E7, NIKS-11E7, NIKS-16E7, and NIKS-18E7 cell lines were generated by lentiviral transduction and puromycin selection. 293FT cells were purchased from Thermo Fisher and cultured in DMEM supplemented with 10% FBS according to the manufacturer's recommendations.
Genome-wide Expression and DNA Methylation Arrays. For gene expression analysis, total RNA was extracted from NIKS, NIKS-16, NIKS-18, and NIKS-16ΔE7 cells using the RNeasy kit (Qiagen) and hybridized to Affymetrix Human Genome U133 Plus 2.0 Array chips as previously described 17 . For methylome analysis, genomic DNA (gDNA) was isolated from NIKS, NIKS-16, NIKS-18, and NIKS-16ΔE7 cells using the DNeasy kit (Qiagen). Bisulfite-converted gDNA was prepared using the EZ DNA Methylation Kit (Zymo Research) and assessed using Illumina Infinium HumanMethylation450 BeadChip Kits according to the manufacturer's protocol. Data processing methods are discussed in the supplemental material.
Methylation Specific PCR (MSP) and in vitro DNA Methylation. Methylation of the HLA-E CGI was analyzed by MSP. gDNA was extracted from NIKS, NIKS-16, and NIKS-16ΔE7 cells using DNeasy Blood & Tissue Kit (Qiagen). 500 ng of the gDNA was used in each bisulfite reaction using the EZ DNA Methylation Kit (Zymo Research) according to the manufacturer's instruction. MSP was performed with primers described in Table S7 and validated using methylated or unmethylated control gDNA. Control DNA was generated by in vitro DNA methylation of gDNA extracted from W12E, W12G, and W12GPXY cells using McrBC endonuclease or M.SssI CpG methyltransferase followed by BstUI digestion (New England Biolabs). In vitro DNA methylation was performed using the M.SssI CpG methyltransferase and methylation efficiency was validated by McrBC or BstUI digestion. For DNA demethylation, NIKS-16 cells were treated daily with 5 μM 5-aza-2′-deoxycytidine (5-aza) for five days.
Plasmids and Lentiviral Constructs. The pCpGL-Basic luciferase reporter vector was a gift from Michael
Rehli (University of Regensburg, Germany) 31 . The four repeats of the cAMP-response element (CRE4X) were synthesized as oligonucleotides and cloned into pCpGL-Basic using BamHI and NcoI 32 . The CXCL14 promoter was cloned into pCpGL-Basic using specific primers (Table S7) between the BamHI and NcoI sites. A new multiple cloning site (MCS) was introduced into the pCpGL-Basic vector in place of the CMV enhancer by PCR-mediated mutagenesis, and the HLA-E CGI was directionally cloned in using specific primers (Table S7) . For generation of E7-expressing NIKS cells, the HPV E7 genes were obtained from Joe Mymryk (University of Western Ontario, Canada) and cloned into lentiviral expression vectors (pCDH-CMV-MCS-EF1-Puro, System Biosciences) between the XbaI and BamHI sites using PCR with specific primers (Table S7) .
Microarray data accession number. The microarray data of gene expression and DNA methylation are accessible in the NCBI GEO database under accession numbers GSE83259 and GSE83261, respectively.
